StocksFin Logo
Sarepta Therapeutics, Inc. country of incorporation
|
|
Mr. Douglas Ingram
|
840 employees
NASDAQ | Healthcare | Biotechnology
Halozyme Therapeutics, Inc. country of incorporation
|
|
Dr. Helen Torley
|
145 employees
NASDAQ | Healthcare | Biotechnology
Q322 reported Nov 2, 2022 Reporting Period
$230.27M 21.6% vs. Q321 Revenues Q322
82.65% -5.7% vs. Q321 Gross Profit Margin
-111.93% ! -340.3% vs. Q321 Net Profit Margin
-73.2M ! 41.1% vs. Q321 Free Cash Flow Q322
$-2.94 ! -390% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Q322 reported Nov 8, 2022 Reporting Period
$208.98M 80.4% vs. Q321 Revenues Q322
77.36% -7.9% vs. Q321 Gross Profit Margin
29.49% -84.2% vs. Q321 Net Profit Margin
68.63M -43.6% vs. Q321 Free Cash Flow Q322
$0.45 -70.6% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
3.81
4.56
Current Ratio
4.36
5.97
Cash Ratio
1.72
1.35
Price to Book
22.48
55.66
Price to Sales
42.07
25.83
Price to Earnings
-9.4
21.9